A Phase II Clinical Trial to Evaluate the Efficacy of BAY 43-9006 With or Without Low Dose Interferon in Metastatic Renal Cell Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 23 Sep 2016
At a glance
- Drugs Sorafenib (Primary) ; Interferon alpha; Interferon alpha-2b
- Indications Renal cell carcinoma
- Focus Biomarker; Therapeutic Use
- 15 Jun 2012 Planned End Date changed from 1 Jun 2014 to 1 May 2014 as reported by ClinicalTrials.gov record.
- 19 Apr 2012 Planned End Date changed from 1 Jun 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 17 Nov 2011 Planned end date changed from 1 Jun 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.